clinical trial · NCT05728736
Acute Effect of Lemborexant on CSF Amyloid-Beta and Tau
Brendan Lucey·phase2·withdrawn
Alzheimer DiseaseLemborexant 25 mgPlacebo
brief summary
This study will look at the effects of lemborexant on Alzheimer's disease biomarkers found in the cerebrospinal fluid (CSF) and blood in individuals who are poor sleepers
started
Mar 1, 2023
primary completion
Sep 27, 2023
completion
Oct 4, 2023
last updated
Nov 8, 2023
detailed description
This study will determine the acute effect of lemborexant on CNS tau phosphorylation and other Alzheimer's disease biomarkers in individuals with poor sleep quality.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol